ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
(2007)
Zeta-associated protein-70 (ZAP-70), mostly assessed by flowcytometry
(FC), recently emerged as reliable prognostic factor
in chronic lymphocytic leukaemia (CLL) at presentation. We
evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry
(IHC) on formalin-fixed bone marrow (BM)
biopsies at diagnosis. At presentation, 117 patients (75%) were
with Binet stage A, 27 (17%) stage B and 12 (8%) stage C.
Median follow-up was 61 months (range 6–242). ZAP-70 was
expressed in neoplastic lymphocytes of 69 patients (44%).
Concordance between ZAP-70 by IHC and ZAP-70 by FC,
immunoglobulin heavy chain variable genes (IGHV) mutational
status and CD38 expression was found in 41/46 (89%), 41/49
(80%) and in 60/88 (68%) tested cases, respectively. ZAP-70
expression significantly correlated with advanced Binet stage
(B–C), diffuse BM infiltration, increased lactate dehydrogenase
(LDH) and b2-microglobulin serum levels and lymphocyte
doubling time o12 months. ZAP-70 positivity was significantly
related to poorer time to progression (median 16 months vs 158
of ZAP-70-negative cases) (Po0.0001) and overall survival
(median 106 months vs not reached) (P¼0.0002); this correlation
was confirmed at multivariate analysis. ZAP-70 expression
correlated with poorer outcome also when evaluated only in the
117 stage A patients. In conclusion, immunohistological
detection of ZAP-70 on formalin-fixed BM biopsies at diagnosis
appears a useful methodological approach to identify patients
with poor prognosis in CLL.
Id prodotto:
34695
Handle IRIS:
11562/233489
depositato il:
18 febbraio 2008
ultima modifica:
15 novembre 2022
Citazione bibliografica:
Zanotti, R; Ambrosetti, Achille; Lestani, M; Ghia, P; Pattaro, C; Remo, Andrea; Zanetti, F; Stella, S; Perbellini, O; Prato, G; Guida, G; CALIGARIS CAPPIO, F; Menestrina, Fabio; Pizzolo, Giovanni; Chilosi, Marco,
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.«Leukemia»
, vol. 21
, 2007
, pp. 102-109